Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
INCY
INCY
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
INCY News
Incyte Unveils Latest Data on Povorcitinib at AAD 2026
Mar 20 2026
Newsfilter
Knight Therapeutics Secures New Drug Approval in Brazil
Mar 17 2026
Globenewswire
Knight Therapeutics Submits MINJUVI Supplemental Application for New Indication
Mar 17 2026
Globenewswire
Companies Like Monster, Palantir, and Expedia That Can Withstand Market Turbulence
Mar 12 2026
Barron's
Stocks Like Monster Beverage and Expedia Poised to Endure Market Fluctuations with Higher Profit Margins.
Mar 12 2026
Barron's
Incyte Receives EU Approval for Zynyz in New Indication
Mar 08 2026
NASDAQ.COM
FDA Rejects Zynyz's Additional Indication Application
Mar 07 2026
seekingalpha
Incyte's Zynyz Drug Receives EU Approval for Rare Cancer
Mar 06 2026
stocktwits
Zynyz Approved by EU for Advanced SCAC Treatment
Mar 06 2026
Newsfilter
Analysis of Growth Drivers in the Biliary Tract Cancer Market
Mar 02 2026
Newsfilter
Positive Opinion for Olumiant in Treating Severe Alopecia Areata in Adolescents
Feb 27 2026
PRnewswire
Olumiant Receives Positive Opinion for Treating Severe Alopecia Areata in Adolescents
Feb 27 2026
Newsfilter
Baker Bros. Advisors Increases Stake in Kymera Therapeutics
Feb 23 2026
Yahoo Finance
Alopecia Areata Market Poised for Significant Growth
Feb 19 2026
Newsfilter
FDA's Accelerated Approval Framework Drives Cancer Treatment Advances
Feb 17 2026
Newsfilter
Atopic Dermatitis Market Growth Insights
Feb 16 2026
Newsfilter
Show More News
